0000000000609010

AUTHOR

Ilja Spellmann

showing 3 related works from this author

Challenging the understanding of significant improvement and outcome in schizophrenia - the concept of reliable and clinically significant change met…

2015

Significant changes of schizophrenia patients during inpatient treatment were evalutaed and compared to established outcome criteria. The concept of reliable and clinically significant change methods was applied to three hundred and ninety-six patients suffering from a schizophrenia spectrum disorder. First, information on whether or not the change of the patient's condition is sufficient in order to declare that it is beyond a measurement error or random effect (= reliable change) was evaluated and in a second step it was observed if the reliable change was clinically meaningful (= clinically significant change). Different Positive and Negative Syndrome Scale for Schizophrenia (PANSS) thre…

medicine.medical_specialtyPositive and Negative Syndrome ScaleRetrospective cohort studyOutcome assessmentmedicine.diseaseOutcome (game theory)3. Good health030227 psychiatry03 medical and health sciencesPsychiatry and Mental health0302 clinical medicineSchizophreniaInternal medicinemedicinesense organsAnalysis of varianceYoung adultskin and connective tissue diseasesPsychology030217 neurology & neurosurgeryClinical psychologySchizophrenia spectrumInternational Journal of Methods in Psychiatric Research
researchProduct

Add-on Antidepressants in the Naturalistic Treatment of Schizophrenia Spectrum Disorder – When, Who, and How?

2017

Abstract The aim of this study was to evaluate antidepressant add-on treatment within the acute treatment of schizophrenia spectrum disorder patients. Antidepressant add-on was evaluated in 365 patients within a naturalistic multicenter study. Patients with/without antidepressant add-on were compared regarding clinical and treatment-related variables, response and remission, and remission of depressive and negative symptoms. The efficacy of antidepressant add-on treatment was furthermore analyzed applying marginal structure models. Twenty-three percent of the patients received antidepressant add-on for a mean duration of 50.28 (33.42) days. Patients with the diagnosis of a schizoaffective d…

AdultMalemedicine.medical_specialtyAdolescentMedizinSchizoaffective disorderDrug synergismYoung Adult03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansPharmacology (medical)Young adultPsychiatryDepressive symptomsAgedDepressionDrug SynergismGeneral MedicineMiddle Agedmedicine.diseaseAntidepressive Agents3. Good health030227 psychiatryClinical trialPsychiatry and Mental healthTreatment OutcomeMulticenter studySchizophreniaAntidepressantFemalePsychology030217 neurology & neurosurgeryAntipsychotic AgentsSchizophrenia spectrumPharmacopsychiatry
researchProduct

Remission in schizophrenia — What are we measuring? Comparing the consensus remission criteria to a CGI-based definition of remission and to remissio…

2019

Despite being recommended for use in clinical trials, the consensus remission criteria were found to leave patients with persisting symptoms, relevant areas of functional impairment and a decreased sense of wellbeing. Therefore, to evaluate the appropriateness of the schizophrenia consensus criteria, a definition of remission based on the Clinical Global Impression Scale (CGI) was developed and remitter subgroups were compared.239 patients with a schizophrenia spectrum disorder were evaluated regarding their remission status after inpatient treatment. Remission in schizophrenia was defined according to the symptom-severity component of the consensus criteria by Andreasen et al. and a CGI ba…

AdultMalePediatricsmedicine.medical_specialtyConsensusMedizinConsensus criteriaSeverity of Illness IndexAsymptomaticYoung Adult03 medical and health sciences0302 clinical medicineRemission criteriaOutcome Assessment Health Caremental disordersmedicineHumansBiological PsychiatryDepression (differential diagnoses)Depressive Disorder Majorbusiness.industryRemission InductionMiddle Agedmedicine.disease030227 psychiatry3. Good healthClinical trialPsychiatry and Mental healthSchizophreniaSchizophreniaClinical Global ImpressionFemalemedicine.symptombusiness030217 neurology & neurosurgeryFollow-Up StudiesSchizophrenia spectrum
researchProduct